ClinicalTrials.gg
CompletedNCT04795726DeFineDRUpdated Nov 2, 2022

A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy, DR)

An interventional study of Finerenone (BAY94-8862) and Placebo in Diabetic Retinopathy, sponsored by Bayer. Completed at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-02.

Sponsored by Bayer · Not applicable, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Diabetic retinopathy (DR) is a diabetes complication caused by damage to the small blood vessels inside the retina at the back of the eye. Diabetic retinopathy may cause mild vision problems or eventually blindness. Diabetes is a condition that makes your blood sugar levels higher than they should be.

In the early stages of diabetic retinopathy - called non-proliferative diabetic retinopathy (NPDR)- increased blood sugar levels lead to damage to the tiny blood vessels of the retina. This damage results in small outpouchings of the vessel lumens leading to rupture. At the same time the blood vessels can leak and making the retina swell and can cause so called macula edema. In these early stages of DR current treatment to reduce the risk of this eye complication is focused on controlling blood sugar levels and blood pressure.

Participants in this study have NPDR, Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD), a condition in which the kidneys become damaged and do not work as they should. These participants are already taking part in one of the phase 3 studies (FIDELIO-DKD and FIGARO-DKD). They study the effect of Finerenone on delaying kidney disease progression and reducing the risk of events that may cause damage to the heart and blood vessels To learn more about the effect of Finerenone on diabetic retinopathy, data from routine eye examinations performed during the two phase 3 studies will be collected and analyzed. All male and female participants included in this study are at least 18 years.

02

Conditions studied

  • Diabetic Retinopathy

Browse trials for

03

In context

Diabetic Retinopathy

779 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.

This study's enrollment of 70 is below the median of 80 across 482 interventional studies indexed under Diabetic Retinopathy.

Browse Diabetic Retinopathy studies →

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed to participate in DeFineDR
  • Included in FIDELIO-DKD or FIGARO-DKD, and with DR as medical history
  • Documented NPDR in at least one eye, as documented by ophthalmological records within 6 months prior to baseline in FIDELIO-DKD or FIGARO-DKD, and up to one month after baseline in FIDELIO-DKD or FIGARO-DKD
  • An ophthalmological assessment available 6 month before or maximum 1 month after the baseline examination in FIDELIO-DKD or FIGARO-DKD, and at least one additional assessment afterwards.

Exclusion criteria

Exclusion Criteria:

  • Participants with PDR, macular edema or anterior segment complications present at baseline in FIDELIO-DKD or FIGARO-DKD in at least one eye.
  • Participants with any documentation of prior or planned retinal laser treatment, intravitreal injection or vitrectomy at baseline in FIDELIO-DKD or FIGARO-DKD in at least one eye.
  • Participants with any other retinal disease documented at baseline in FIDELIO-DKD or FIGARO-DKD in at least one eye that would likely interfere with the study objectives (e.g. neovascular age-related macular degeneration or retinal vein occlusion).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Treatment group

    Patients received treatment in phase 3 clinical trials FIDELIO-DKD (16244) and FIGARO-DKD (17530).

    Drug: Finerenone (BAY94-8862)

  • Placebo comparator
    Placebo group

    Patients received placebo in phase 3 clinical trials FIDELIO-DKD (16244) and FIGARO-DKD (17530).

    Drug: Placebo

Interventions

  • 10 mg or 20 mg Finerenone tablet to be given orally, once daily, administered in the FIDELIO-DKD or FIGARO-DKD clinical trial.

  • DrugPlacebo

    Matching placebo to be taken orally, once daily, administered in the FIDELIO-DKD or FIGARO-DKD clinical trial.

06

What researchers measure

Primary outcomes

  1. Proportion of participants with progression of non-proliferative diabetic retinopathy (NPDR)

    Progression of non-proliferative diabetic retinopathy (NPDR) defined by the occurrence of vision-threatening events i.e. proliferative diabetic retinopathy (PDR), diabetic macular edema (DME), anterior segment neovascularization (ASN) until the end of Year 2 after start of treatment

    Time frame: After start of treatment until end of Year 2

Secondary outcomes

  1. Proportion of participants with progression of non-proliferative diabetic retinopathy (NPDR)

    Progression of non-proliferative diabetic retinopathy (NPDR) defined by the occurrence of vision-threatening events i.e. proliferative diabetic retinopathy (PDR), diabetic macular edema (DME), anterior segment neovascularization (ASN) until the end of Year 1 after start of treatment

    Time frame: After start of treatment until end of Year 1

  2. Proportion of participants with progression of NPDR to Proliferative Diabetic Retinopathy (PDR)

    Time frame: After start of treatment until end of Year 1, and until the end of Year 2

  3. Proportion of participants with diabetic macular edema (DME)

    Time frame: After start of treatment until end of Year 1 and end of Year 2

  4. Proportion of participants with anterior segment neovascularization (ASN)

    Time frame: After start of treatment until end of Year 1 and end of Year 2

  5. Change in severity of diabetic retinopathy (DR)

    Severity grade of DR: No DR NPDR (mild or moderate) NPDR (severe) PDR

    Time frame: From strat of treatment to the end of Year 1 and end of Year 2

07

Study locations

11 sites
  • Med Centre Diamedical 2013
    Dimitrovgrad, 6400, Bulgaria
  • MHAT Sveta Karidad
    Plovdiv, 4004, Bulgaria
  • MHAT Hadzhi Dimitar
    Sliven, 8800, Bulgaria
  • MHAT Dr. Bratan Shukerov AD
    Smolyan, 4700, Bulgaria
  • DCC Aleksandrovska
    Sofia, 1431, Bulgaria
  • MCOMH Preventsia-2000
    Stara Zagora, 6000, Bulgaria
  • MHAT Sveti Pantaleymon - Yambol
    Yambol, 8600, Bulgaria
  • Southmead Hospital
    Bristol, Avon BS10 5NB, United Kingdom
  • St Richard's Hospital
    Chichester, West Sussex PO19 6SE, United Kingdom
  • Royal London Hospital
    London, E1 1BB, United Kingdom
  • King's College Hospital - NHS Foundation Trust
    London, SE5 9RS, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Jun 2021, 3 months.

Of 126 interventional studies with no phase under Diabetic Retinopathy, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 60. This study's 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2021
First posted
Mar 12, 2021
StartActual
Mar 10, 2021
Primary completionActual
Jun 30, 2021
CompletionActual
Jun 30, 2021
Last update
Nov 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04795726
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Mar 12, 2021
Start date
Mar 10, 2021
Primary completion
Jun 30, 2021
Completion
Jun 30, 2021
Last update
Nov 2, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Finerenone

Start the discussion